NCT05909800View on ClinicalTrials.gov

Prolonged Remission Induced by Phenofibrate in Children Newly Diagnosed With Type 1 Diabetes.

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Phenofibrate

Administred orally, once daily, for 12 months.

DRUG

Placebo

Administred orally, once daily, for 12 months.

Trial Locations (2)

02-091

RECRUITING

Clinical department of pediatric diabetology and paediatrics, DSK UCKWUM, Warsaw

04-730

RECRUITING

Diabetology Department, Children's Memorial Health Institute, Warsaw

All Listed Sponsors
collaborator

Children's Memorial Health Institute, Poland

OTHER

lead

Medical University of Warsaw

OTHER

NCT05909800 - Prolonged Remission Induced by Phenofibrate in Children Newly Diagnosed With Type 1 Diabetes. | Biotech Hunter | Biotech Hunter